dr. M. (Hilde) Jalving

Faculty of Medical Sciences

Telephone:

+31 50 361 2821

E-mail:

m.jalving umcg.nl

ORCID Research Portal

Publications

128P - Whole blood transcriptomics identifies transcriptional patterns linked to outcomes in patients receiving immune checkpoint inhibitors

Hone Lopez, S., Loipfinger, S., Bhattacharya, A., Jalving, M., Oosting, S. F., Hiltermann, J., de Bruyn, M., de Vries, E. G. E., de Haan, J.-J. & Fehrmann, R., 14-Sept-2024, In: Annals of Oncology. 35, Supplement 2, p. S266 1 p.

Research output: Contribution to journal › Meeting Abstract › Academic

B cells critical for outcome in high grade serous ovarian carcinoma

Vledder, A., Paijens, S. T., Loiero, D., Maagdenberg, A., Duiker, E. W., Bart, J., Hendriks, A. M., Jalving, M., Werner, N., van Rooij, N., Plat, A., Wisman, G. B. A., Yigit, R., Roelofsen, T., Kruse, A. J., de Lange, N. M., Koelzer, V. H., de Bruyn, M. & Nijman, H. W., 22-Aug-2024, (E-pub ahead of print) In: International Journal of Cancer. 12 p.

Research output: Contribution to journal › Article › Academic › peer-review

Causality and functional relevance of BRCA1 and BRCA2 pathogenic variants in non-high-grade serous ovarian carcinomas

Kramer, C., Lanjouw, L., Ruano, D., Ter Elst, A., Santandrea, G., Solleveld-Westerink, N., Werner, N., van der Hout, A. H., de Kroon, C. D., van Wezel, T., Berger, L. P. V., Jalving, M., Wesseling, J., Smit, V., de Bock, G. H., van Asperen, C. J., Mourits, M. J. E., Vreeswijk, M., Bart, J. & Bosse, T., Feb-2024, In: The Journal of Pathology. 262, 2, p. 137-146 10 p.

Research output: Contribution to journal › Article › Academic › peer-review

Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol

Verkerk, K., Geurts, B. S., Zeverijn, L. J., van der Noort, V., Verheul, H. M. W., Haanen, J. B. A. G., van der Veldt, A. A. M., Eskens, F. A. L. M., Aarts, M. J. B., van Herpen, C. M. L., Jalving, M., Gietema, J. A., Devriese, L. A., Labots, M., Barjesteh van Waalwijk van Doorn-Khosrovani, S., Smit, E. F. & Bloemendal, H. J., Apr-2024, In: The Lancet Regional Health - Europe. 39, 12 p., 100875.

Research output: Contribution to journal › Article › Academic › peer-review

Environmentally sustainable prescribing: recommendations for EU pharmaceutical legislation

Piët, J. D., Booth, A., Donker, E. M., de Ponti, F., Lunghi, C., Poluzzi, E., Janssen, B. J. A., Tun, S., Bekker, C., Dima, L., Costa, J., Jalving, M., Oude Munnink, T. H., van den Bemt, P. M. L. A., Labriffe, M., van Emden, T., van Waardenburg, V., Likic, R., Richir, M. & van Agtmael, M. A.& 2 others, Moermond, C. T. A. & Tichelaar, J., Oct-2024, In: The Lancet Planetary Health. 8, 10, p. e715-e716 2 p.

Research output: Contribution to journal › Letter › Academic › peer-review

Everolimus decreases [U-13C]glucose utilization by pyruvate carboxylase in breast cancer cells in vitro and in vivo.

Ariaans, G., Tiersma, J. F., Evers, B., Gerding, A., Waaijer, S. J. H., Koster, R. A., Touw, D. J., Bakker, B. M., Reijngoud, D.-J., de Jong, S. & Jalving, M., Apr-2024, In: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 173, 10 p., 116362.

Research output: Contribution to journal › Article › Academic › peer-review

Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement

Vermeulen, O. C. B., Brouwer, E., Slart, R. H. J. A., Sandovici, M., Rutgers, A., Hilterman, T. J., Hiddinga, B., Oosting, S. F., Jalving, M., de Heij, A. H., Knapen, D. G., Hospers, G. A. P. & van der Geest, K. S. M., 9-Feb-2024, (E-pub ahead of print) In: Rheumatology (Oxford, England). 9 p., keae099.

Research output: Contribution to journal › Erratum

Immune Checkpoint Inhibitors in Endometrial Cancer: A Cinderella Story

Colombo, N., Caruso, G. & Jalving, M., Aug-2024, In: Annals of Oncology. 35, 8, p. 686-688 3 p.

Research output: Contribution to journal › Editorial › Academic › peer-review

Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic variant carriers

Stroot, I. A. S., Bart, J., Hollema, H., Jalving, M., Wagner, M. M., Yigit, R., van Doorn, H. C., de Hullu, J. A., Gaarenstroom, K. N., van Beurden, M., van Lonkhuijzen, L. R. C. W., Slangen, B. F. M., Zweemer, R. P., Gómez García, E. B., Ausems, M. G. E. M., Boere, I. A., van Hest, L. P., Duijkers, F. A. M., van Asperen, C. J. & Schmidt, M. K.& 7 others, Wevers, M. R., Ruijs, M. W. G., Devilee, P., Collée, J. M., HEBON investigators, I., de Bock, G. H. & Mourits, M. J. E., Aug-2024, In: Gynecologic Oncology. 187, p. 198-203 6 p.

Research output: Contribution to journal › Article › Academic › peer-review

Long-Term Survival in Patients With Advanced Melanoma

van Not, O. J., van den Eertwegh, A. J. M., Jalving, H., Bloem, M., Haanen, J. B., van Rijn, R. S., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blank, C. U., Boers-Sonderen, M. J., de Groot J W B, J. W., Hospers, G. A. P., Kapiteijn, E., Leeneman, B., D, P., Stevense-den Boer, M., van der Veldt, A. A. M., Vreugdenhil G, G., Wouters, M. W. J. M. & Blokx, W. A. M.& 1 others, Suijkerbuijk, K. P. M., 1-Aug-2024, In: Jama network open. 7, 8, 13 p., e2426641.

Research output: Contribution to journal › Article › Academic › peer-review